Clinical Trial Update: Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus [Phase 2]

View source ↗

Summary

Phase 2 trial of alisertib for recurrent or persistent uterine leiomyosarcoma completed; results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Corpus Leiomyosarcoma
• Uterine Corpus Sarcoma

Drugs mentioned

• Alisertib (alisertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2015-07-17